Adrenal Hypercortisolism: A Closer Look at Screening, Diagnosis, and Important Considerations of Different Testing Modalities by I. Chiodini et al.
ISSN 2472-1972
Adrenal Hypercortisolism: A Closer Look at
Screening, Diagnosis, and Important
Considerations of Different
Testing Modalities
Iacopo Chiodini,1,2 Arelys Ramos-Rivera,3 Alan O. Marcus,4 and Hanford Yau5
1Department of Clinical Sciences and Community Health, University of Milan, 20122Milan, Italy; 2Unit
for Bone Metabolism Diseases and Diabetes and Laboratory of Endocrine and Metabolic Research,
Istituto di Ricovero e Cura a Carattere Scientifico Istituto Auxologico Italiano, 20149 Milan, Italy;
3Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida
32827; 4South Orange County Endocrinology, Laguna Hills, California 92653; and 5Division of
Endocrinology, University of California, San Francisco (UCSF Fresno), Fresno, California 93701
ORCiD numbers: 0000-0001-7594-3300 (I. Chiodini); 0000-0001-6711-2929 (H. Yau).
Although prolonged hypercortisolism is associated with increased mortality and substantial morbidity,
the clinical signs and symptoms are wide ranging and often nonspecific, contributing to challenges in
diagnosis, as well as treatment delays. Greater awareness is needed among clinicians to help identify
which patients should undergo biochemical screening for excess cortisol. Several biochemical tests are
available, each with important caveats that should be considered in the context of the individual
patient. Cortisol secretion varies widely, further complicating the biochemical diagnosis of hyper-
cortisolism, which relies on the use of definitive cutoff values. Patients with hypercortisolism resulting
from adrenal adenomas, including those discovered incidentally, often do not present with overt
Cushingoid features (plethora, striae, muscle weakness, moon facies, etc.). However, the consequences
of prolonged exposure to even slight elevations in cortisol levels are profound, including increased risk
of diabetes, hypertension, fractures, cardiovascular events, and mortality. Because most cases of
hypercortisolism resulting from an adrenal adenoma can be managed, it is imperative to identify
patients at risk and initiate testing early for the best outcomes. The aim of this report is to increase
awareness of the indications for screening for hypercortisolism and to review the biochemical screening
tests and diagnosis for hypercortisolism associated with adrenal adenomas.
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Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
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Adrenal adenomas are common causes of autonomous cortisol secretion, and patients often
present without Cushingoid features (e.g., bruising, proximal muscle weakness, purple
striae, etc.). Even without manifestation of overt clinical phenotypes, the consequences of
hypercortisolism can be profound. Prolonged exposure to slight elevation in cortisol levels is
associated with increased risk of diabetes, hypertension, fragility fractures, cardiovascular
events, andmortality [1–5]. Because progression to overt Cushing syndrome is relatively rare
[6, 7], these patients are often described separately as having “subclinical Cushing syndrome.”
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dehydroepiandrosterone sulfate; DST, dexamethasone suppression test; LC-MS/MS, liquid chromatography-tandem mass spec-
trometry; LDDST, low-dose dexamethasone suppression test; LNSC, late-night salivary cortisol; ODST, overnight dexamethasone
suppression test; T2DM, type 2 diabetes mellitus; UFC, urinary-free cortisol.
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However, this term is inadequate because it does not accurately define or convey the sig-
nificances of the disease [6] or the importance of identifying at-risk patients. Instead, we have
chosen to use the more general term, “hypercortisolism,” as we recognize that the clinical
spectrum of Cushing syndrome is broad and that the diagnosis of hypercortisolism is chal-
lenging regardless of the classification.
The prevalence of hypercortisolism is estimated to be 5% to 30% in patients with adrenal
masses, serendipitously found by imaging for unrelated diseases (adrenal “incidentalomas”),
such as kidney stones or abdominal or back pain [6]. Adrenal incidentalomas are thought to
be present in 4% to 7% of adults, and therefore, the prevalence of hypercortisolism in adults
may be between 0.2% and 2.0% [6]. However, patients with incidentally discovered adrenal
adenomas frequently do not receive biochemical workups to detect hypercortisolism, so this
incidence rate may be underreported. Thus, this review will focus on hypercortisolism caused
by adrenal adenomas and the screening and diagnosis of this patient population. Imaging
recommendations to differentiate adrenal adenoma from carcinoma or to support a bio-
chemical diagnosis and direct treatment will not be included.
1. Indications for Screening
The signs and symptoms of hypercortisolism are nonspecific and are shared with many
conditions that affect the general population. These include hypertension, glucose
intolerance/type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, and osteoporosis [8–10]
(Table 1). The determination of whether these comorbidities are related to cortisol excess in a
given patient is not clinically straightforward. Additionally, because of the perceived rarity of
Cushing syndrome, clinical suspicion of hypercortisolism as the primary cause of disease
often is not considered in the differential diagnosis. The Endocrine Society guidelines rec-
ommend screening for hypercortisolism in patients who present with the following: adrenal
incidentaloma compatible with adenoma, conditions inconsistent with the patient’s age (e.g.,
diabetes, hypertension, or osteoporosis), or multiple and progressive clinical features (e.g.,
weight gain, diabetes, depression, acne, facial fullness, etc.) [11].
A. Adrenal Adenomas Incidentally Discovered
Various radiology and clinical guidelines have suggested routine clinical and hormonal
workup for incidentally discovered adrenal adenomas [12]. However, adherence to such
guidelines is inadequate, with only 30% of patients with adrenal adenomas referred for
hormonal workup [13]. Although most adrenal incidentalomas are benign, clinical and
Table 1. Signs and Symptoms of Hypercortisolism: Clinical Features [8–10]
General Neuropsychiatric
Obesity Emotional lability
Hypertension Euphoria
Skin Depression
Hirsutism Psychosis
Plethora Gonadal dysfunction
Striae Menstrual disorders
Acne Impotence/decreased libido
Bruising Metabolic
Musculoskeletal Glucose intolerance
Low BMD for age and sex Diabetes
Weakness Hyperlipidemia
Backache Polyuria
Fragility fracture Kidney stones
Abbreviation: BMD, bone mineral density.
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hormonal evaluations are essential to assessment of the functionality and clinical impact of
the adenomas. Clinicians should review radiology reports for mentions of adrenal adenomas
and if found, should conduct a thorough clinical and biochemical workup as outlined below.
B. High Clinical Suspicion
B-1. Unusual features for the patient’s age
A patient younger than 50 years old with poorly controlled or resistant diabetes or hyper-
tension should prompt further evaluation for hypercortisolism [11, 14]. A young patient with
unexplained osteoporosis or a history of nontraumatic or fragility fractures should also be
evaluated, as cortisol plays a major role in the bone and calcium homeostasis [14, 15].
B-2. Multiple progressive features
Because hypercortisolism can result in the entire clinical spectrum of metabolic syndrome, it
is easy to overlook the contribution of cortisol and to view the progression of signs and
symptoms as the natural progression of metabolic syndrome. Hypercortisolism should be
suspected if patients have multiple uncontrolled conditions, such as “resistant” diabetes,
hypertension, osteoporosis, or depression, regardless of age [15–17].
Chronic hypercortisolism, even in the so-called “subclinical” stage, can have pleiotropic
effects onmajor peripheral tissues responsible for glucose homeostasis [18]. Consideration for
patients to undergo secondary biochemical workups for hypercortisolism in the setting of
resistant diabetes should be undertaken when the need for antiglycemic therapies and/or
insulin therapy is significantly high (e.g., $2 units/kg/day) or incongruent with the expected
degree of insulin resistance or obesity that a patient has. Whereas we do not advocate routine
screening of all patients with T2DM for hypercortisolism, meta-analyses andmultiple single-
center studies have consistently demonstrated the prevalence of hypercortisolism to be ;2%
to;9% in these patients in the absence of any discriminatory “classic” clinical features (easy
bruising, facial plethora, proximal muscle weakness, and/or striae) [19–21]. Whereas these
percentages seem small, they translate to an estimate between 575,000 and .2.5 million
people with T2DM in the United States possibly with secondary diabetes as a result of
underlying hypercortisolism.
The prevalence of hypercortisolism in the general hypertensive patient population has
been reported as ;1% [22], although a higher rate (8%) has been reported in patients with
resistant hypertension (i.e., uncontrolled with three antihypertensives, including a diuretic)
[23]. In patients with resistant hypertension, workup for primary sources should include
assessment of cortisol.
The prevalence of hypercortisolism in patients with osteoporosis varies from 0.6% to 4.8%
[24–27], and a prevalence rate up to 10.8% has been reported in patients with low bone
mineral density (BMD) and fragility fractures [27]. Clinicians should consider screening for
hypercortisolism in patients with low BMD for their age or weight. Screening may also be
considered in patients with greater than expected declines in BMD or with BMD that is
resistant to treatment [27].
2. Biochemical Evaluation
Patients with newly discovered adrenal adenomas and/or signs and symptoms leading to a
suspicion of hypercortisolism should undergo biochemical screening [11]. Ideally, diagnostic
assays should be used in combination with a degree of clinical suspicion for hypercortisolism
to reduce the likelihood of false-positive results. A flowchart may be used as a practical
approach (Fig. 1).
The first step in the evaluation of patients for hypercortisolism is to exclude any exogenous
causes of cortisol excess, such as corticosteroid medications. Other medications may include
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glucocorticoid-containing skin creams (including bleaching agents), some herbalmedications,
joint/nerve injections, and medroxyprogesterone acetate [11]. Next, it is important to select
and perform the appropriate screening test to optimize diagnostic sensitivity and specificity
without “over testing” the patient. After ruling out exogenous causes, the dexamethasone
suppression test (DST), late-night salivary cortisol (LNSC), and 24-hour urinary-free cortisol
(UFC) are used to diagnose hypercortisolism. They all rely on the pathophysiology of the
hypothalamic-pituitary-adrenal axis; they also all possess limitations related to their sen-
sitivity, specificity, and/or convenience [11] (Table 2). In addition, cortisol secretion fluctu-
ates, and thus, assessments are subject to variability over time [6]. Because no single test is
perfect, the performance of more than one test, either sequentially or simultaneously, is a
common practice. In any case, in patients without the classical signs and symptoms of overt
cortisol excess and in the absence of possible interference caused by other medications, it is
the authors’ opinion that the DST test should be preferred for diagnosis of the presence of
hypercortisolism [14].
A. DST
The recommended screening test for evaluation of biochemical hypercortisolism in most
patients is the 1-mg overnight DST (ODST) with a diagnostic cutoff of 1.8 mg/dL (50 nM) or
greater. Whereas some clinicians have cited a historic cutoff of #5 mg/dL (138 nM) as
“normal,” the use of this historic cutoff misclassified up to 15% of patients with false-negative
results [6, 28]. The current cutoff of 1.8 mg/dL (50 nM) enhances test sensitivity to.95% and
test specificity of 80% [14, 29]. Noting the challenges in the establishment of a single di-
agnostic cutoff, some guidelines have also recommended interpretation of the 1-mg ODST
result as a continuous rather than strictly categorical variable [8].
With ODST, 1 mg oral dexamethasone is taken before bedtime (;2300 hours). Serum
cortisol levels are measured the next morning (between 0800 and 0900 hours) [11]. Ad-
vantages of this modality include drug availability, ease of testing, and patient tolerance.
Figure 1. Biochemical evaluation of suspected adrenal hypercortisolism. Assessment of
hypercortisolism, based on biochemical assays, should include a degree of clinical suspicion to
reduce the likelihood of false-positive results. *DST, dexamethasone suppression test; to be
used as a unique, first-line screening test in the absence of overt signs and/or symptoms of
hypercortisolism. **Repeat every 6 months if clinically suggestive of hypercortisolism.
ACTH, adrenocorticotropic hormone; CRH, corticotropin-releasing hormone; DHEAS,
dehydroepiandrosterone sulfate; LNSC, late-night salivary cortisol; UFC, urinary-free cortisol.
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Alternatively, particularly in patients with T2DM and/or obesity or in patients with
equivocal results, a 2-day, low-dose DST (LDDST) can be used where 0.5 mg dexamethasone
is taken every 6 hours (starting from ;0900 hours) for 2 days, followed by cortisol mea-
surement, 6 hours after the last dose was given. This test is cumbersome andmore difficult to
perform. In these patients, a prolonged dexamethasone administration may be needed to
inhibit corticotropin-releasing hormone (CRH) release. A concordant result of $1.8 mg/dL
(50 nM) is confirmation of hypercortisolism [14]. An LDDST should be validated with a serum
dexamethasone level of .220 ng/dL (5.6 nM) to avoid the possibility of a false-positive
result [30].
These tests have high diagnostic specificity when serum cortisol levels are .1.8 mg/dL
(50 nM). It is important to keep in mind that these fixed dexamethasone doses do not take into
consideration differences in dexamethasone absorption, volume of distribution, and metab-
olism, all of which are influenced by gastrointestinal function, body weight, and hepatic and
renal function [9]. Therefore,we recommend evaluation of serumdexamethasone levelswith all
DSTs (or reflexively obtaining a dexamethasone level in patients with an initial positive DST).
B. LNSC
This test assesses the circadian rhythm of the hypothalamic-pituitary-adrenal axis [9].
Cortisol levels are expected to peak upon awakening in the morning (0700 to 0900 hours) and
taper off during the day and are at their lowest during the late night (2300 to 0100 hours) [31,
32]. Hence, it was hypothesized that taking a late-night cortisol readingwould help to identify
those with abnormal elevated levels when cortisol should be at its lowest. For patients with
overt cortisol excess, the LNSC has a high sensitivity and specificity [11] (see Table 2).
However, the use of the LNSC may not be as accurate as previously thought in patients with
de novo and recurrent/persistent Cushing disease, as shown by the wide fluctuations in
sequentiallymeasured LNSC in a recent prospective analysis [33]. Unfortunately, in patients
with suspected hypercortisolism associated with adrenal incidentalomas, the LNSC test does
not add much information because of its lack of sensitivity (22.7%) [34]. A recent study by
Ceccato et al. [35], showed that daily cortisol exposure, evaluated using area under the curve
from multiple saliva collections, was increased in the morning in patients with adrenal
adenomas and a serum cortisol .1.8 mg/dL (50 nM) after DST, leading to reduced corti-
cotropin levels. However, cortisol rhythm was preserved in these patients, offering further
support that LNSC is not a useful screening test for less severe hypercortisolism [35].
However, it could be used as a confirmative test if the first results are abnormal [34, 36, 37].
The best validated assays used in the United States are an ELISA and an assay performed
by liquid chromatography-tandem mass spectrometry (LC-MS/MS) [11]. For either of these
assay techniques, late-night (2300 to 2400 hours) values above 145 ng/dL (4 nM) suggest
hypercortisolism, although individual diagnostic thresholds may apply. Patients are advised
to collect saliva samples on two separate evenings. A saliva sample is easy to obtain in the
privacy of the patient’s home, substantially reducing ambient stress levels. Furthermore, the
sample can be stored in the refrigerator for several days and mailed to the laboratory at room
temperature [11, 38, 39].
Nonetheless, adherence to the timing of sample collection has been shown to be an issue [40].
Not following the collection protocol to take the sample late at night significantly affects results.
Another confounder is that normal circadian rhythms are disrupted in persons with altered
sleep patterns, such as shift workers, which causes abnormally elevated levels [41]. In these
cases, samples should be taken at a time that correlateswith themiddle of their sleep cycle [11].
Additionally smokers have been shown to have higher LNSC levels than nonsmokers, and
stress immediately before collection can cause cortisol levels to spike [11, 42–45] (Table 3).
C. 24-Hour UFC
The 24-hour UFC test measures cortisol levels in urine over the course of a day. Normal,
24-hour UFC is a common laboratory finding in patients with less severe hypercortisolism,
doi: 10.1210/js.2018-00382 | Journal of the Endocrine Society | 1101
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because the dysregulated and increased production of cortisol does not typically exceed the
plasma-binding capacity of free cortisol, limiting the appearance of cortisol in the urine [46].
As a result of the lower specificity and sensitivity comparedwith othermethods, especially for
less severe disease, the use of this test is secondary to other testing assays [9]. Patients are
instructed to discard the first void of the day and then collect all urine over the course of
24 hours, with the final collection being the first void of the next day. This aspect of the test
can be inconvenient for those who cannot stay home for an entire day. The sample should be
stored in the refrigerator until it can be brought to the clinic, which should occur within a few
days. Samples aremeasured for cortisol by either an antibody-based immunoassay or LC-MS/
MS, with thresholds for diagnosis dependent on the specific test used [11]. LC-MS/MS
provides the most accurate assessment, but its use in routine practice is limited. Given
that UFC testing only measures free cortisol, it is not affected by conditions or medications
(i.e., oral estrogen) that increase bound cortisol levels found in serum [11]. However, high
fluid intake, contamination, incomplete urine collection, certain drugs, and decreased glo-
merular filtration rate (,60 mL/min) may affect the accuracy of this test [9, 11, 47, 48].
Diagnostic accuracy can be improved by the concurrent measurement of urinary creatinine,
with low levels indicating incomplete collection [48]. Urine collection should be repeated
when creatinine levels are,1.5 g/day (,13.3 mmol/day) in men and,1 g/day (8.8 mmol/day)
in women [49].
D. Plasma ACTH
ACTH is often used to differentiate ACTH-dependent (Cushing disease or ectopic ACTH)
from ACTH-independent (adrenal) hypercortisolism. In ACTH-independent hyper-
cortisolism, the negative-feedback suppression of pituitary corticotrophs by cortisol leads to
reduced plasma ACTH levels.
In patients with plasma ACTH levels between 5 pg/mL (1.1 pM) and 20 pg/mL (4.4 pM), a
CRH stimulation test may be recommended [9]. The premise is that normal corticotrophs are
Table 3. Confounders to Accurate Results for the Main Testing Platforms [11, 42–45]
LNSC UFC DST
Drugs/conditions that give false positives
Exercise/stress X X X
Smoking X
Disrupted sleep (e.g., shift work) X
Topical hydrocortisone (contamination of sample) X
Proteinuria X
Polyuria X
Anticonvulsants X X
Fenofibrate X
Synthetic glucocorticoids X
Pregnancy X X X
Alcoholism X X X
Depression X X X
Estrogen therapy X
Drugs that induce CYP3A4 X
Drugs that inhibit 11b-hydroxysteroid
dehydrogenase type 2 (e.g., licorice,
carbenoxolone)
X X
Drugs/conditions that give false negatives
Renal disease X X
Urinary tract infection X
Liver failure X
Drugs that inhibit CYP3A4 X
Abbreviation: CYP3A4, cytochrome P450 3A4.
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suppressed as a result of mild cortisol excess, and therefore, levels of ACTH will not elevate
after provocative stimulation. In this setting, an ACTH rise above 30 pg/mL (6.6 pM) is
diagnostic for an ACTH-dependent form of hypercortisolism. This test is particularly useful
in patients with bilateral adrenal hyperplasia, which may also be sustained by an increased
ACTH secretion (generally by a pituitary tumor). In these cases, the CRH test may be useful
for evidencing the tendency of the adrenal masses toward an autonomous cortisol secretion,
therefore helping to determine the treatment of choice. However, it must be noted that the
CRH test is an expensive procedure, and therefore, it is not widely performed, especially in
nonacademic centers. The need for a CRH test should always be ascertained by physicians
with expertise in diagnosing Cushing syndrome.
E. DHEAS
Dehydroepiandrosterone sulfate (DHEAS) is an androgen precursor that is regulated, in part,
by ACTH [50, 51]. Low-serumDHEAS levels have been shown to be a marker of excess cortisol
in patients with adrenal adenomas (ACTH-independent hypercortisolism) [50, 52]. In a ret-
rospective analysis of patients with adrenal adenomas conducted by Yener et al. [50], low
DHEAS [,40 mg/dL (1.1 mM)] was found to be significantly predictive of hypercortisolism. In a
more recent retrospective analysis of patients with adrenal adenomas, age-adjusted DHEAS
assessment demonstrated comparable sensitivity (100%) and greater specificity (91.9%) than
the 1-mg DST (.99% and 88.6%, respectively) for the diagnosis of hypercortisolism [52].
Although not recommended as an initial diagnostic test, DHEAS may be considered as a
supportive assessment [11]. Considerations for this test include its long half-life and that it is
not subject to circadian variations [51]. DHEAS levels also decrease with age.
3. Considerations in Making a Diagnosis
As the signs and symptoms of hypercortisolism are indistinguishable from a variety of other
conditions, a differential diagnosis is often only realized after other etiologies have been
exhausted. In fact, a definitive diagnosis in patients with either adrenal or pituitary etiol-
ogies can be up to be 2 years from onset of symptoms [53–55]. On average, patients wait
;1 year from symptom onset before they seek medical advice [53]. Diagnosis is complicated
by the selection of symptoms that patients report. Patients tend to report only those
symptoms related to the specialty of the practitioner and use nonspecific layperson’s terms
(e.g., “trouble with joints”) [53]. In addition, although 83% of patients initially go to their family
physician to address their symptoms, almost 70% of patients ultimately are diagnosed by an
endocrinologist, and substantial differences are observed between the number of consulted
physicians in rural and urban places of living, suggesting differences in familiarity with
hypercortisolism among specialties [53]. Another study found that, among physicians at-
tending endocrinology meetings, the probability of diagnosing hypercortisolism was based on
number of years in practice [56].
Whereas the most recent clinical guidelines regarding diagnosis of hypercortisolism in
patients with adrenal incidentalomas, from 2016, suggest that patients undergo screening
with the ODST [8], a recent study of 57 centers from 26 European countries found that testing
protocols varied considerably across practices [57]. In addition to test-platform availability,
clinical experience was found to contribute to the choice of diagnostic test. It was also found
that testing protocols changed over time. In fact, some authors have suggested that multiple
tests may be the best approach to diagnose hypercortisolism accurately [58].
4. Conclusion
General screening of the population at large for hypercortisolism is not recommended.
However, for those with signs or symptoms indicative of hypercortisolism, appropriate
testing is critical, as quality of life is significantly affected in those with the condition, and
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early initiation of treatment has been shown to relieve the burden of disease [59, 60].
Hypercortisolism represents a spectrum of cortisol levels and associated morbidity that
challenges clinicians in making a diagnosis. Signs and symptoms are vague and nonspecific
and do not always correlate with biochemical results. Nevertheless, suspicion should be
raised when patients present with nondescript symptoms that resist conventional therapy.
A variety of biochemical tests are available to assist withmaking a diagnosis; however, they
each have limitations, and the results can sometimes be equivocal. Given the detrimental
effects associated with prolonged hypercortisolism, clinicians must consider interpretation of
biochemical tests in the context of the patient’s medical history and clinical presentation. As
most cases can be managed or even cured [61], it is imperative that clinicians learn to identify
patients at risk and initiate testing as early as possible to afford the best outcomes.
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